Effect of tailored antiplatelet therapy on periprocedural myonecrosis in patients with diabetes mellitus (from the DM-verify now trial)

American Journal of Cardiology

Volumn 110, Issue 12, 2012, Pages 1749-1755

  Suh, Jung Won ^a   Kim, Chi Hoon ^a   Oh, Il Young ^a   Yoon, Chang Hwan ^a   Kim, Kwang Il ^a   Cho, Young Seok ^a   Youn, Tae Jin ^a   Chae, In Ho ^a   Choi, Dong Ju ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PURINERGIC P2Y12 RECEPTOR; TROPONIN I;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; INSULIN TREATMENT; LABORATORY TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYOCARDIAL INFARCTION; POSTOPERATIVE HEMORRHAGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE PRICING; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL PLATELET REACTIVITY; RETROPERITONEAL HEMORRHAGE; RISK REDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

BIOLOGICAL MARKERS; CREATINE KINASE, MB FORM; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; TROPONIN;

EID: 84870293422     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.08.009     Document Type: Article

References (26)

1. D.J. Kereiakes, P.A. Gurbel Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention JACC Cardiovasc Interv 1 2008 111 121
2. P.A. Gurbel, K.P. Bliden, K.A. Zaman, J.A. Yoho, K.M. Hayes, U.S. Tantry Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study Circulation 111 2005 1153 1159
3. T. Cuisset, M. Hamilos, J. Sarma, G. Sarno, E. Wyffels, M. Vanderheyden, E. Barbato, J. Bartunek, B. De Bruyne, W. Wijns Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris Am J Cardiol 101 2008 1700 1703
4. F. Mangiacapra, G. Patti, A. Peace, L. Gatto, V. Vizzi, E. Ricottini, A. D'Ambrosio, O. Muller, E. Barbato, G. Di Sciascio Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention Am J Cardiol 106 2010 619 623
5. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
6. A.D. Michelson, M.D. Linden, M.I. Furman, Y. Li, M.R. Barnard, M.L. Fox, W.C. Lau, T.J. McLaughlin, A.L. Frelinger Evidence that pre-existent variability in platelet response to ADP accounts for clopidogrel resistance J Thromb Haemost 5 2007 75 81
7. F. Mangiacapra, E. Barbato, G. Patti, L. Gatto, V. Vizzi, E. Ricottini, A. D'Ambrosio, W. Wijns, G. Di Sciascio Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention JACC Cardiovasc Interv 3 2010 318 323
8. G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, G. Di Sciascio Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
9. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, J.P. Levisay, A. Ernst, N.S. Sawhney, R.A. Schatz, P.S. Teirstein Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
10. D.J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R.K. Charlton, Y. Suzuki, L.C. Box, S.B. Shoemaker, M.M. Zenni, L.A. Guzman, T.A. Bass A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur Heart J 29 2008 2202 2211
11. K.W. Park, K.H. Jeon, S.H. Kang, I.Y. Oh, H.J. Cho, H.Y. Lee, H.J. Kang, S.K. Park, B.K. Koo, B.H. Oh, Y.B. Park, H.S. Kim Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study) Am J Cardiol 108 2011 1556-1163
12. 12 assay after coronary stenting in patients with and without acute myocardial infarction JACC Cardiovasc Interv 5 2011 259 267
13. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
14. R. Marcucci, A.M. Gori, R. Paniccia, B. Giusti, S. Valente, C. Giglioli, P. Buonamici, D. Antoniucci, R. Abbate, G.F. Gensini Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
15. W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, S. James, J. Knuuti, J. Lopez-Sendon, J. Marco, L. Menicanti, M. Ostojic, M.F. Piepoli, C. Pirlet, J.L. Pomar, N. Reifart, F.L. Ribichini, M.J. Schalij, P. Sergeant, P.W. Serruys, S. Silber, M. Sousa Uva, D. Taggart, M. Sousa Uva, D. Taggart Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
16. F. Mangiacapra, B. De Bruyne, O. Muller, C. Trana, A. Ntalianis, J. Bartunek, G. Heyndrickx, G. Di Sciascio, W. Wijns, E. Barbato High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention JACC Cardiovasc Interv 3 2010 35 40
17. A. Prasad, J. Herrmann Myocardial infarction due to percutaneous coronary intervention N Engl J Med 364 2011 453 464
18. M.J. Price, P.B. Berger, P.S. Teirstein, J.F. Tanguay, D.J. Angiolillo, D. Spriggs, S. Puri, M. Robbins, K.N. Garratt, O.F. Bertrand, M.E. Stillabower, J.R. Aragon, D.E. Kandzari, C.T. Stinis, M.S. Lee, S.V. Manoukian, C.P. Cannon, N.J. Schork, E.J. Topol, E.J. Topol GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
19. D. Trenk, G.W. Stone, M. Gawaz, A. Kastrati, D.J. Angiolillo, U. Müller, G. Richardt, J.A. Jakubowski, F.J. Neumann A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
20. Q. Cai, K.A. Skelding, A.T. Armstrong Jr, D. Desai, G.C. Wood, J.C. Blankenship Predictors of periprocedural creatine kinase-myocardial band elevation complicating elective percutaneous coronary intervention Am J Cardiol 99 2007 616 620
21. G.G. Babu, J.M. Walker, D.M. Yellon, D.J. Hausenloy Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection Eur Heart J 32 2011 23 31
22. N.R. Desai, D.L. Bhatt The state of periprocedural antiplatelet therapy after recent trials JACC Cardiovasc Interv 3 2010 571 583
23. Y. Wu, Y. Shi, H. Wu, C. Bian, Q. Tang, G. Xu, J. Yang Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis PLoS ONE 6 2011 e20759
24. J. Mehilli, A. Kastrati, H. Schühlen, A. Dibra, F. Dotzer, N. von Beckerath, H. Bollwein, J. Pache, J. Dirschinger, P.P. Berger, A. Schömig Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel Circulation 110 2004 3627 3635
25. S.R. Steinhubl, K. Kottke-Marchant, D.J. Moliterno, M.L. Rosenthal, N.K. Godfrey, B.S. Coller, E.J. Topol, A.M. Lincoff Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention Circulation 100 1999 1977 1982
26. S.R. Steinhubl, J.D. Talley, G.A. Braden, J.E. Tcheng, P.J. Casterella, D.J. Moliterno, F.I. Navetta, P.B. Berger, J.J. Popma, G. Dangas, R. Gallo, D.C. Sane, J.F. Saucedo, G. Jia, A.M. Lincoff, P. Theroux, D.R. Holmes, P.S. Teirstein, D.J. Kereiakes Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the gold (AU-Assessing Ultegra) multicenter study Circulation 103 2001 2572 2578